Tag: iCLAS

Adagio Medical Receives CE Mark Approval for its iCLAS™ Cryoablation System and Prepares for European Commercial Launch

LAGUNA HILLS, Calif., June 1, 2020 /PRNewswire/ — Adagio Medical, Inc., announces that it has received CE Mark approval for its ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) for the endocardial treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation and atrial flutter. “More than half of all atrial fibrillation (AF) patients are diagnosed with PsAF. There […]

Adagio Medical Completes Chronic Pre-Clinical Atrial Fibrillation Study Using Ultra-Low Temperature Cryoablation Technology

LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ — Adagio Medical, Inc., the developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration with the LIRYC Research Institute of Bordeaux, […]